California legalization of doctor-prescribed suicide threatens vulnerable

Image from page 463 of “Internal medicine; a work for the practicing physician on diagnosis and treatment, with a complete Desk index” (1920)
hepatitis prognosis

Download source background in full size at Internet Archive Book Images
Identifier: internalmedicine02wils
Title: Internal medicine; a work for the practicing physician on diagnosis and treatment, with a complete Desk index
Year: 1920 (1920s)
Authors: Wilson, J. C. (James Cornelius), 1847-1934 Potter, Nathaniel Bowditch, 1869-1919
Subjects: Medicine Diagnosis
Publisher: Philadelphia, London, J. B. Lippincott Company
Contributing Library: Columbia University Libraries
Digitizing Sponsor: Open Knowledge Commons

View Book Page: Book Viewer
About This Book: Catalog Entry
View All Images: All Images From Book

Click here to view book online to see this illustration in context in a browseable online version of this book.

Text Appearing Before Image:
les and muddy or subicteroidhue,—fades hepatica,—the sparechest and thin arms, the distendedbelly with its conspicuous super-ficial veins, and the diminishedarea of liver dulness leave nodoubt of the nature of the malady.In the latter the jaundice, thefairly well-preserved nutrition, thebig liver without ascites, and occa-sional irregular fever render the diagnosis equally clear. The two conditionsare clinically distinct because they are the manifestations of essentiallydifferent pathological lesions. The one thing that these lesions have in com-mon is an overgrowth of the interstitial connective tissue of the liver. Itmight be said that they have nothing in common clinically save that theyare diseases of the liver. Yet they are described respectively as the atrophicform and the hypertrophic form of the same affection, hepatic cirrhosis.The diagnosis of hepatic capsulitis—the capsular cirrhosis of authors-—is usually attended by insuperable difficulties. The symptoms are those

Text Appearing After Image:
Fig. 314.—Ascites due to atrophic cirrhosis of theliver.—Jefferson Hospital. NEW GROWTHS IN Till: I.I i:i{. 4i:i of the atiopliic Ioi-m of cliidiiic imnsiil ial ncplirit is. .laiirulicc is notusually |)rs(Mit. Vw kidneys arc <i!aiuilai-. This cniiditioti may he usso-(•iat(Ml with pcrisplcMiitis and prolifcratixc pcritoiutis. DiPFKKENTiAL.— Adhosjvc pylophlel)itis closely resembles the atrophicform of interstitial hepatitis. The etioln pei-itoneal (^iTusion d(>vel()ps and reforms after tappiiiti, as wasshown in a case nn-ently in my service in the Pennsylvania Hospital, areimportant in the diflei-ential diagnosis. It is said that thrombosis of the])ortal vein is followed l)y an atrophy of the li-er, which renders the diag-nosis di Hi cult. In the cases that have come under my observation deathhas occurred in the course of a few weeks, and t«he liver was of normal size. Prognosis.—In the atrophic form the ou

Note About Images
Please note that these images are extracted from scanned page images that may have been digitally enhanced for readability – coloration and appearance of these illustrations may not perfectly resemble the original work.

Thanks Internet Archive Book Images for sharing!
California legalization of doctor-prescribed suicide threatens vulnerable
Consequently, this so-called safeguard has allowed the killing of diabetics, those with HIV, or those with hepatitis simply because without treatment they would die within six months—even though with treatment they could live much longer. Assisting …
Read more here.

Pembrolizumab Shows Response in Metastatic Nasopharyngeal Carcinoma
Over a fifth of patients with previously treated advanced nasopharyngeal carcinoma showed a measurable response, when treated with pembrolizumab, an immune checkpoint inhibitor, according to a study that was reported at this year's European Cancer …
Read more here.

MiR expression profiles of paired primary colorectal cancer and metastases by
… expressed in advanced CRC were identified using NGS. In addition, miR expression profiles of pCRC and metastatic lesions are highly comparable and may be of similar predictive value for prognosis or response to treatment in patients with advanced …
Read more here.

Novel Immunotherapies on the Horizon in HCC
Given that most patients with HCC do not receive a diagnosis until the disease is at an advanced stage, and only liver resection and transplantation are considered curative, there is an urgent clinical need to improve the therapy landscape. Although …
Read more here.
WHO issues its first hepatitis B treatment guidelines
12 March 2015 ¦ GENEVA – WHO today issued its first-ever guidance for the treatment of chronic hepatitis B, a viral infection which is spread through blood and body fluids, attacking the liver and resulting in an estimated 650 000 deaths each year …
Read more here.

Phil Lesh, Grateful Dead Founding Member, Announces Fight With Cancer
Although Lesh described his prognosis as being positive, the rocker was forced to cancel the PLF shows scheduled for Oct 24/25. However, he … In 1998, Phil Lesh underwent a liver transplant after suffering from a chronic hepatitis C infection …
Read more here.
New HCV NS5A inhibitor EDP-239 looks good in early studies, more evidence
Other researchers reported that HCV co-infection and progressive liver disease contribute to mortality among people with HIV, offering further evidence in support of prompt hepatitis C treatment. ICAAC was once one of the major annual venues for the …
Read more here.

High standards of care associated with reduced mortality risk of patients with HIV
Quality of care (QOC) in the first twelve months after entering HIV care is associated with longer-term mortality risk, investigators from the US Department of Veterans Affairs report in the online edition of Clinical Infectious Diseases. Patients who …
Read more here.

Biotech Stocks with Pessimistic Trend: Gilead Sciences, Inc. (NASDAQ:GILD
… ASTRAL-4) evaluating a once-daily, fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF) with velpatasvir (VEL), an investigational pangenotypic NS5A inhibitor, for the treatment of genotype 1-6 chronic hepatitis C …
Read more here.

Leave a Reply